{"nctId":"NCT01187498","briefTitle":"Behavioral Treatment of Overactive Bladder in Men","startDateStruct":{"date":"2005-01"},"conditions":["Overactive Bladder"],"count":143,"armGroups":[{"label":"Behavioral Training","type":"EXPERIMENTAL","interventionNames":["Behavioral: Behavioral training"]},{"label":"Drug Therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Oxybutynin chloride, extended-release"]}],"interventions":[{"name":"Behavioral training","otherNames":["Behavioral treatment"]},{"name":"Oxybutynin chloride, extended-release","otherNames":["Antimuscarinic medication"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male\n* Community-dwelling\n* Veteran\n* Self-reported urgency\n* Self-reported frequent urination\n* Mean of \\> 8 voids per 24-hour day on bladder diary\n* Able to come to clinic\n\nExclusion Criteria:\n\n* Urologic surgery in the past 6 months\n* Nonambulatory (unless has independent transfer skills)\n* Flow rate \\< 5mL at baseline and \\< 10mL/sec after run-in (on simple uroflowmetry)\n* Post-void residual urine volume \\> 250mL at baseline and \\> 150mL after run-in (on bladder ultrasound)\n* Continual leakage\n* Urinary tract infection (growth of \\> 100,000 colonies per ml of a urinary pathogen on urine culture). May be reconsidered after treatment and negative culture.\n* Fecal impaction\n* Poorly controlled diabetes (glycosylated hemoglobin \\>9 within last 3 months)\n* Hematuria on microscopic examination in the absence of infection\n* Any unstable medical condition (particularly: decompensated congestive heart failure, malignant arrhythmias, unstable angina)\n\n  \\-- Impaired mental status (\\< 24 on Folstein's Mini-Mental State Exam)\n* Narrow angle glaucoma\n* Gastric retention (by medical history)\n* Hypersensitivity to tamsulosin or oxybutynin\n* Current use of anticholinergic agents for detrusor instability. May be reconsidered after 2-week wash-out.\n* If on diuretic, dose has not been stable for at least three months\n* Sleep apnea, unless surgically corrected","healthyVolunteers":false,"sex":"MALE","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"24-hour Voiding Frequency","description":"Mean voiding frequency per 24 hours derived from 7-day bladder dairy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"2.5"},{"groupId":"OG001","value":"9.5","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Change in Nocturia Frequency","description":"Change in frequency of nocturia episodes based on 7-day bladder diary","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.70","spread":".72"},{"groupId":"OG001","value":"-.32","spread":"1.28"}]}]}]},{"type":"SECONDARY","title":"Change in Urgency Severity","description":"Indevus Urgency Severity Scale incorporated into the 7-day bladder diary. Scores for urgency severity ranged from 0 to 3:\n\n0: None-no urgency\n\n1. Mild-awareness of urgency, but is easily tolerated.\n2. Moderate-enough urgency discomfort that it interferes with or shortens usual activity\n3. Severe-extreme urgency discomfort that abruptly stops all activities or tasks.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".04","spread":".58"},{"groupId":"OG001","value":"-.15","spread":".42"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Frequency of Urge Incontinence","description":"Percent change in frequency of urge incontinence episodes based on 7-day bladder diary. Percent change was calculated as (\\[frequency at baseline\\] - \\[frequency at 8 weeks\\]) / (frequency at baseline).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":".25"},{"groupId":"OG001","value":"75.6","spread":".36"}]}]}]},{"type":"SECONDARY","title":"Change on American Urological Association (AUA) Symptom Index","description":"Change in score on American Urological Association (AUA) Symptom Index (baseline to week 8). The index measures lower urinary tract symptoms. Scores range from 0 to 35, with higher scores indicating worse symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"4.6"},{"groupId":"OG001","value":"3.2","spread":"5.6"}]}]}]},{"type":"SECONDARY","title":"Patient Global Perception of Improvement (GPI)","description":"Patient global perception of improvement (\"much better\" to \"much worse\")","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Satisfaction","description":"Patient global rating of satisfaction with progress in treatment (\"completely satisfied\" to \"very dissatisfied\")","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Rating of Activity Restriction","description":"Patient global rating of activity restriction (\"not at all\" to \"all the time\")","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Report of Symptom Distress","description":"Patient report of how disturbed they were by symptoms (\"not at all\" to \"extremely\")","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Rating of Bothersomeness of Side Effects","description":"Patient global rating of how bothersome their side effects were (\"no side effects\" to \"extremely bothersome\")","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Desire for Alternate Treatment","description":"Patient response to \"Do you wish to receive another form of treatment?\" (yes)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":73},"commonTop":[]}}}